Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Last trade$7.00
Day change-$0.28 (-3.85%)
Day range$6.89 – $7.47
Volume218,862
Market cap$278M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$277.88M
Price / earnings
—
Price / book
5.37×
Price / sales
8.12×
EV / sales
6.39×
EV / EBITDA
-4.61×
Profitability
Earnings per share
-$1.10
Return on assets
-34.79%
Return on equity
-80.88%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.43×
Current ratio
10.47×
Quick ratio
10.47×
Cash ratio
9.88×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
—
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DTIL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2026 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$34.2M
$13K
$18K
$18K
$29K
$638K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$34.2M
$13K
$18K
$18K
$29K
$638K
Selling, general and administrative
$7.68M
$6.77M
$7.23M
$7.33M
$9.13M
$9.13M
$8.55M
$9.58M
Research and development
$12.75M
$12.39M
$14.46M
$13.35M
$12.77M
$12.77M
$13.59M
$15.91M
Total operating expenses
$20.43M
$19.16M
$21.7M
$20.68M
$21.9M
$21.9M
$22.14M
$25.48M
Operating income
-$20.43M
-$19.16M
$12.51M
-$20.67M
-$21.88M
-$21.88M
-$22.11M
-$24.85M
Interest expense
-$307K
-$300K
-$348K
-$362K
-$358K
-$358K
-$354K
-$392K
Income before taxes
-$7.59M
-$32.65M
$19.25M
-$21.77M
-$23.52M
-$23.52M
-$20.57M
-$17.75M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.59M
-$32.65M
$20.13M
-$21.77M
-$23.52M
-$23.52M
-$20.57M
-$17.75M
Net income attributable to common shareholders
-$7.59M
-$32.65M
$20.13M
-$21.77M
-$23.52M
-$23.52M
-$20.57M
-$17.75M
EBITDA
-$20.43M
-$19.16M
$12.85M
-$20.67M
-$21.5M
-$21.88M
-$21.72M
-$24.39M
Basic earnings per share
-$0.28
-$1.26
$1.05
-$1.84
-$2.13
-$2.13
-$2.21
-$2.21
Diluted earnings per share
-$0.28
-$1.26
$1.05
-$1.84
-$2.13
-$2.13
-$2.21
-$2.17
Recent news
Company coverage with links to the original publishers.
CPTx announced the appointment of Matt Kane as Chief Financial Officer. Kane brings extensive experience in gene editing and cell therapy, with a track record of raising over $500 million in equity financing and securing strategic partnerships valued at over $4 billion. He previously served as CEO of Celyad Oncology, Tune Therapeutics, and Precision Biosciences. Kane will lead CPTx's financing and partnering activities as the company advances its non-viral DNA-based in vivo CAR T therapies toward clinical studies.
The global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety concerns remain significant challenges.
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.
The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.
The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.